APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metastatic Ovarian Cancer Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metastatic Ovarian Cancer Drug Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchMetastatic Ovarian Cancer Drug Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Metastatic Ovarian Cancer Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Metastatic Ovarian Cancer Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metastatic Ovarian Cancer Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Metastatic Ovarian Cancer Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Metastatic Ovarian Cancer Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metastatic Ovarian Cancer Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metastatic Ovarian Cancer Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metastatic Ovarian Cancer Drug market include Adgero Biopharmaceuticals Inc, Cellceutix Corporation, F. Hoffmann-La Roche Ltd., Immune Design Corp., Millennium Pharmaceuticals Inc, MolMed S.p.A., Natco Pharma Limited, Northwest Biotherapeutics, Inc. and Sumitomo Dainippon Pharma Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metastatic Ovarian Cancer Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metastatic Ovarian Cancer Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metastatic Ovarian Cancer Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metastatic Ovarian Cancer Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Metastatic Ovarian Cancer Drug Segment by Company

Adgero Biopharmaceuticals Inc

Cellceutix Corporation

F. Hoffmann-La Roche Ltd.

Immune Design Corp.

Millennium Pharmaceuticals Inc

MolMed S.p.A.

Natco Pharma Limited

Northwest Biotherapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

VG Life Sciences, Inc.

Pfizer Inc.

Richter Gedeon Nyrt.

Eisai Co., Ltd.

Metastatic Ovarian Cancer Drug Segment by Type

E-749

Crizotinib

LV-305

G-305

CMB-305

Others

Metastatic Ovarian Cancer Drug Segment by Application

Clinic

Hospital

Others

Metastatic Ovarian Cancer Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Metastatic Ovarian Cancer Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metastatic Ovarian Cancer Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metastatic Ovarian Cancer Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Metastatic Ovarian Cancer Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Ovarian Cancer Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metastatic Ovarian Cancer Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Ovarian Cancer Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metastatic Ovarian Cancer Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metastatic Ovarian Cancer Drug industry.

Chapter 3: Detailed analysis of Metastatic Ovarian Cancer Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metastatic Ovarian Cancer Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metastatic Ovarian Cancer Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metastatic Ovarian Cancer Drug Industry Trends Table 2. Metastatic Ovarian Cancer Drug Industry Drivers Table 3. Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges Table 4. Metastatic Ovarian Cancer Drug Industry Restraints Table 5. Global Metastatic Ovarian Cancer Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metastatic Ovarian Cancer Drug Revenue Share by Company (2021-2026) Table 7. Global Metastatic Ovarian Cancer Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Company (2021-2026) Table 9. Global Metastatic Ovarian Cancer Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Metastatic Ovarian Cancer Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metastatic Ovarian Cancer Drug Key Company Manufacturing Base & Headquarters Table 12. Global Metastatic Ovarian Cancer Drug Company, Product Type & Application Table 13. Global Metastatic Ovarian Cancer Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metastatic Ovarian Cancer Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of E-749 Table 18. Significant Companies of Crizotinib Table 19. Significant Companies of LV-305 Table 20. Significant Companies of G-305 Table 21. Significant Companies of CMB-305 Table 22. Significant Companies of Others Table 23. Global Metastatic Ovarian Cancer Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Metastatic Ovarian Cancer Drug Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Metastatic Ovarian Cancer Drug Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Type (2021-2026) Table 27. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Type (2027-2032) Table 28. Global Metastatic Ovarian Cancer Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Metastatic Ovarian Cancer Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Metastatic Ovarian Cancer Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Metastatic Ovarian Cancer Drug Sales Value Share by Type (2021-2026) Table 32. Global Metastatic Ovarian Cancer Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Others Table 36. Global Metastatic Ovarian Cancer Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Metastatic Ovarian Cancer Drug Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Metastatic Ovarian Cancer Drug Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Application (2021-2026) Table 40. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Application (2027-2032) Table 41. Global Metastatic Ovarian Cancer Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Metastatic Ovarian Cancer Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Metastatic Ovarian Cancer Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Metastatic Ovarian Cancer Drug Sales Value Share by Application (2021-2026) Table 45. Global Metastatic Ovarian Cancer Drug Sales Value Share by Application (2027-2032) Table 46. Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2026) & (K Units) Table 48. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2021-2026) Table 49. Global Metastatic Ovarian Cancer Drug Sales by Region (2027-2032) & (K Units) Table 50. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2027-2032) Table 51. Global Metastatic Ovarian Cancer Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Metastatic Ovarian Cancer Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Metastatic Ovarian Cancer Drug Sales Value Share by Region (2021-2026) Table 54. Global Metastatic Ovarian Cancer Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Metastatic Ovarian Cancer Drug Sales Value Share by Region (2027-2032) Table 56. Global Metastatic Ovarian Cancer Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Metastatic Ovarian Cancer Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Metastatic Ovarian Cancer Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Metastatic Ovarian Cancer Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Metastatic Ovarian Cancer Drug Sales by Country (2021-2026) & (K Units) Table 61. Global Metastatic Ovarian Cancer Drug Sales Market Share by Country (2021-2026) Table 62. Global Metastatic Ovarian Cancer Drug Sales by Country (2027-2032) & (K Units) Table 63. Global Metastatic Ovarian Cancer Drug Sales Market Share by Country (2027-2032) Table 64. Global Metastatic Ovarian Cancer Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Metastatic Ovarian Cancer Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Metastatic Ovarian Cancer Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Metastatic Ovarian Cancer Drug Sales Value Market Share by Country (2027-2032) Table 68. Adgero Biopharmaceuticals Inc Company Information Table 69. Adgero Biopharmaceuticals Inc Business Overview Table 70. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio Table 72. Adgero Biopharmaceuticals Inc Recent Development Table 73. Cellceutix Corporation Company Information Table 74. Cellceutix Corporation Business Overview Table 75. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio Table 77. Cellceutix Corporation Recent Development Table 78. F. Hoffmann-La Roche Ltd. Company Information Table 79. F. Hoffmann-La Roche Ltd. Business Overview Table 80. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 82. F. Hoffmann-La Roche Ltd. Recent Development Table 83. Immune Design Corp. Company Information Table 84. Immune Design Corp. Business Overview Table 85. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio Table 87. Immune Design Corp. Recent Development Table 88. Millennium Pharmaceuticals Inc Company Information Table 89. Millennium Pharmaceuticals Inc Business Overview Table 90. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio Table 92. Millennium Pharmaceuticals Inc Recent Development Table 93. MolMed S.p.A. Company Information Table 94. MolMed S.p.A. Business Overview Table 95. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio Table 97. MolMed S.p.A. Recent Development Table 98. Natco Pharma Limited Company Information Table 99. Natco Pharma Limited Business Overview Table 100. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio Table 102. Natco Pharma Limited Recent Development Table 103. Northwest Biotherapeutics, Inc. Company Information Table 104. Northwest Biotherapeutics, Inc. Business Overview Table 105. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 107. Northwest Biotherapeutics, Inc. Recent Development Table 108. Sumitomo Dainippon Pharma Co., Ltd. Company Information Table 109. Sumitomo Dainippon Pharma Co., Ltd. Business Overview Table 110. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 112. Sumitomo Dainippon Pharma Co., Ltd. Recent Development Table 113. VG Life Sciences, Inc. Company Information Table 114. VG Life Sciences, Inc. Business Overview Table 115. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 117. VG Life Sciences, Inc. Recent Development Table 118. Pfizer Inc. Company Information Table 119. Pfizer Inc. Business Overview Table 120. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio Table 122. Pfizer Inc. Recent Development Table 123. Richter Gedeon Nyrt. Company Information Table 124. Richter Gedeon Nyrt. Business Overview Table 125. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio Table 127. Richter Gedeon Nyrt. Recent Development Table 128. Eisai Co., Ltd. Company Information Table 129. Eisai Co., Ltd. Business Overview Table 130. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio Table 132. Eisai Co., Ltd. Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Metastatic Ovarian Cancer Drug Distributors List Table 136. Metastatic Ovarian Cancer Drug Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Metastatic Ovarian Cancer Drug Product Image Figure 2. Global Metastatic Ovarian Cancer Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metastatic Ovarian Cancer Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metastatic Ovarian Cancer Drug Sales (2021-2032) & (K Units) Figure 5. Global Metastatic Ovarian Cancer Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Metastatic Ovarian Cancer Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. E-749 Image Figure 10. Crizotinib Image Figure 11. LV-305 Image Figure 12. G-305 Image Figure 13. CMB-305 Image Figure 14. Others Image Figure 15. Global Metastatic Ovarian Cancer Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Metastatic Ovarian Cancer Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Metastatic Ovarian Cancer Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Metastatic Ovarian Cancer Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Metastatic Ovarian Cancer Drug Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Others Image Figure 24. Global Metastatic Ovarian Cancer Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Metastatic Ovarian Cancer Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Metastatic Ovarian Cancer Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Metastatic Ovarian Cancer Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Metastatic Ovarian Cancer Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Metastatic Ovarian Cancer Drug Sales Value Share by Application (2021-2032) Figure 30. Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Metastatic Ovarian Cancer Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Metastatic Ovarian Cancer Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Metastatic Ovarian Cancer Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Metastatic Ovarian Cancer Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Metastatic Ovarian Cancer Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Metastatic Ovarian Cancer Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Metastatic Ovarian Cancer Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Metastatic Ovarian Cancer Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Metastatic Ovarian Cancer Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Metastatic Ovarian Cancer Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Metastatic Ovarian Cancer Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Metastatic Ovarian Cancer Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Metastatic Ovarian Cancer Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • E-749
  • Crizotinib
  • LV-305
  • G-305
  • CMB-305
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Adgero Biopharmaceuticals Inc
  • Cellceutix Corporation
  • F. Hoffmann-La Roche Ltd.
  • Immune Design Corp.
  • Millennium Pharmaceuticals Inc
  • MolMed S.p.A.
  • Natco Pharma Limited
  • Northwest Biotherapeutics, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • VG Life Sciences, Inc.
  • Pfizer Inc.
  • Richter Gedeon Nyrt.
  • Eisai Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metastatic Ovarian Cancer Drug Sales Value (2021-2032)
  4. 1.2.2 Global Metastatic Ovarian Cancer Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Metastatic Ovarian Cancer Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metastatic Ovarian Cancer Drug Market Dynamics
  1. 2.1 Metastatic Ovarian Cancer Drug Industry Trends
  2. 2.2 Metastatic Ovarian Cancer Drug Industry Drivers
  3. 2.3 Metastatic Ovarian Cancer Drug Industry Opportunities and Challenges
  4. 2.4 Metastatic Ovarian Cancer Drug Industry Restraints
3 Metastatic Ovarian Cancer Drug Market by Company
  1. 3.1 Global Metastatic Ovarian Cancer Drug Company Revenue Ranking in 2025
  2. 3.2 Global Metastatic Ovarian Cancer Drug Revenue by Company (2021-2026)
  3. 3.3 Global Metastatic Ovarian Cancer Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Metastatic Ovarian Cancer Drug Average Price by Company (2021-2026)
  5. 3.5 Global Metastatic Ovarian Cancer Drug Company Ranking (2024-2026)
  6. 3.6 Global Metastatic Ovarian Cancer Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Metastatic Ovarian Cancer Drug Company Product Type and Application
  8. 3.8 Global Metastatic Ovarian Cancer Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metastatic Ovarian Cancer Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metastatic Ovarian Cancer Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metastatic Ovarian Cancer Drug Market by Type
  1. 4.1 Metastatic Ovarian Cancer Drug Type Introduction
  2. 4.1.1 E-749
  3. 4.1.2 Crizotinib
  4. 4.1.3 LV-305
  5. 4.1.4 G-305
  6. 4.1.5 CMB-305
  7. 4.1.6 Others
  8. 4.2 Global Metastatic Ovarian Cancer Drug Sales Volume by Type
  9. 4.2.1 Global Metastatic Ovarian Cancer Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Metastatic Ovarian Cancer Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Metastatic Ovarian Cancer Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Metastatic Ovarian Cancer Drug Sales Value by Type
  13. 4.3.1 Global Metastatic Ovarian Cancer Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Metastatic Ovarian Cancer Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Metastatic Ovarian Cancer Drug Sales Value Share by Type (2021-2032)
5 Metastatic Ovarian Cancer Drug Market by Application
  1. 5.1 Metastatic Ovarian Cancer Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Metastatic Ovarian Cancer Drug Sales Volume by Application
  6. 5.2.1 Global Metastatic Ovarian Cancer Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Metastatic Ovarian Cancer Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Metastatic Ovarian Cancer Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Metastatic Ovarian Cancer Drug Sales Value by Application
  10. 5.3.1 Global Metastatic Ovarian Cancer Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Metastatic Ovarian Cancer Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Metastatic Ovarian Cancer Drug Sales Value Share by Application (2021-2032)
6 Metastatic Ovarian Cancer Drug Regional Sales and Value Analysis
  1. 6.1 Global Metastatic Ovarian Cancer Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metastatic Ovarian Cancer Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Metastatic Ovarian Cancer Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Metastatic Ovarian Cancer Drug Sales by Region (2027-2032)
  5. 6.3 Global Metastatic Ovarian Cancer Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metastatic Ovarian Cancer Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metastatic Ovarian Cancer Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metastatic Ovarian Cancer Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Metastatic Ovarian Cancer Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metastatic Ovarian Cancer Drug Sales Value (2021-2032)
  12. 6.6.2 North America Metastatic Ovarian Cancer Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metastatic Ovarian Cancer Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Metastatic Ovarian Cancer Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metastatic Ovarian Cancer Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metastatic Ovarian Cancer Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metastatic Ovarian Cancer Drug Sales Value (2021-2032)
  21. 6.9.2 South America Metastatic Ovarian Cancer Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metastatic Ovarian Cancer Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metastatic Ovarian Cancer Drug Sales Value Share by Country, 2025 VS 2032
7 Metastatic Ovarian Cancer Drug Country-level Sales and Value Analysis
  1. 7.1 Global Metastatic Ovarian Cancer Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metastatic Ovarian Cancer Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metastatic Ovarian Cancer Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Metastatic Ovarian Cancer Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Metastatic Ovarian Cancer Drug Sales by Country (2027-2032)
  6. 7.4 Global Metastatic Ovarian Cancer Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metastatic Ovarian Cancer Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metastatic Ovarian Cancer Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metastatic Ovarian Cancer Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metastatic Ovarian Cancer Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metastatic Ovarian Cancer Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Adgero Biopharmaceuticals Inc
  2. 8.1.1 Adgero Biopharmaceuticals Inc Company Information
  3. 8.1.2 Adgero Biopharmaceuticals Inc Business Overview
  4. 8.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
  6. 8.1.5 Adgero Biopharmaceuticals Inc Recent Developments
  7. 8.2 Cellceutix Corporation
  8. 8.2.1 Cellceutix Corporation Company Information
  9. 8.2.2 Cellceutix Corporation Business Overview
  10. 8.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Product Portfolio
  12. 8.2.5 Cellceutix Corporation Recent Developments
  13. 8.3 F. Hoffmann-La Roche Ltd.
  14. 8.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 8.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 8.3.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  18. 8.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 8.4 Immune Design Corp.
  20. 8.4.1 Immune Design Corp. Company Information
  21. 8.4.2 Immune Design Corp. Business Overview
  22. 8.4.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Product Portfolio
  24. 8.4.5 Immune Design Corp. Recent Developments
  25. 8.5 Millennium Pharmaceuticals Inc
  26. 8.5.1 Millennium Pharmaceuticals Inc Company Information
  27. 8.5.2 Millennium Pharmaceuticals Inc Business Overview
  28. 8.5.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product Portfolio
  30. 8.5.5 Millennium Pharmaceuticals Inc Recent Developments
  31. 8.6 MolMed S.p.A.
  32. 8.6.1 MolMed S.p.A. Company Information
  33. 8.6.2 MolMed S.p.A. Business Overview
  34. 8.6.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Product Portfolio
  36. 8.6.5 MolMed S.p.A. Recent Developments
  37. 8.7 Natco Pharma Limited
  38. 8.7.1 Natco Pharma Limited Company Information
  39. 8.7.2 Natco Pharma Limited Business Overview
  40. 8.7.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Product Portfolio
  42. 8.7.5 Natco Pharma Limited Recent Developments
  43. 8.8 Northwest Biotherapeutics, Inc.
  44. 8.8.1 Northwest Biotherapeutics, Inc. Company Information
  45. 8.8.2 Northwest Biotherapeutics, Inc. Business Overview
  46. 8.8.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  48. 8.8.5 Northwest Biotherapeutics, Inc. Recent Developments
  49. 8.9 Sumitomo Dainippon Pharma Co., Ltd.
  50. 8.9.1 Sumitomo Dainippon Pharma Co., Ltd. Company Information
  51. 8.9.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
  52. 8.9.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments
  55. 8.10 VG Life Sciences, Inc.
  56. 8.10.1 VG Life Sciences, Inc. Company Information
  57. 8.10.2 VG Life Sciences, Inc. Business Overview
  58. 8.10.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  60. 8.10.5 VG Life Sciences, Inc. Recent Developments
  61. 8.11 Pfizer Inc.
  62. 8.11.1 Pfizer Inc. Company Information
  63. 8.11.2 Pfizer Inc. Business Overview
  64. 8.11.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Product Portfolio
  66. 8.11.5 Pfizer Inc. Recent Developments
  67. 8.12 Richter Gedeon Nyrt.
  68. 8.12.1 Richter Gedeon Nyrt. Company Information
  69. 8.12.2 Richter Gedeon Nyrt. Business Overview
  70. 8.12.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product Portfolio
  72. 8.12.5 Richter Gedeon Nyrt. Recent Developments
  73. 8.13 Eisai Co., Ltd.
  74. 8.13.1 Eisai Co., Ltd. Company Information
  75. 8.13.2 Eisai Co., Ltd. Business Overview
  76. 8.13.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product Portfolio
  78. 8.13.5 Eisai Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metastatic Ovarian Cancer Drug Value Chain Analysis
  2. 9.1.1 Metastatic Ovarian Cancer Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metastatic Ovarian Cancer Drug Sales Mode & Process
  6. 9.2 Metastatic Ovarian Cancer Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metastatic Ovarian Cancer Drug Distributors
  9. 9.2.3 Metastatic Ovarian Cancer Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst